ALLHAT Cholesterol Arm Supports Current Treatment Guidelines
Executive Summary
The ALLHAT study results include an endorsement of current recommendations for aggressive use of lipid-lowering agents
You may also be interested in...
ALLHAT Study Brings Calls For Comparative Trials, Greater Focus On Costs
The ALLHAT hypertension trial is bringing renewed calls for more comparative trials of pharmaceutical agents
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials